Evidence map›Paper›PMID 42867482›Full record

ArticleEpilepsia open2026

Exploring medical food supplementation as an adjunct strategy for microbiota restoration and seizure reduction in CDKL5 deficiency disorder.

Elisa Borghi, Matteo Domenico Marsiglia, Francesca Triva, Emerenziana Ottaviano, Ilaria Viganò, Miriam Nella Savini, Valentino Costabile, Aglaia Vignoli

Abstract read
In one paragraph

Article in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elisa BorghiDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.ORCID https://orcid.org/0000-0002-1893-0455
Matteo Domenico MarsigliaDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Francesca TrivaDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Emerenziana OttavianoDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Ilaria ViganòChild Neurology - Epilepsy Centre, ASST Santi Paolo Carlo, Member of ERN-Epicare, Milan, Italy.
Miriam Nella SaviniChild Neurology - Epilepsy Centre, ASST Santi Paolo Carlo, Member of ERN-Epicare, Milan, Italy.
Valentino CostabileUnit of Microbiology and Virology, ASST Santi Paolo e Carlo, Milan, Italy.
Aglaia VignoliDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.ORCID https://orcid.org/0000-0003-4638-4663

Funding

Fondazione Telethon GSA23G001
6 · The paper itself

Abstract

objectivesCDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy characterized by early-onset, treatment-resistant seizures and severe neurodevelopmental impairment. Increasing evidence suggests that alterations in the gut-brain axis may contribute to disease pathophysiology, raising interest in microbiota-targeted interventions. In this study, we evaluated the effects of a prebiotic-based nutritional intervention on clinical outcomes, gut microbiota composition, and fatty acid profiles in individuals with CDD.

methodsThirteen participants with drug-resistant epilepsy were enrolled (one male; median age, 12 years [IQR, 8.8-17.5]), and ten completed the longitudinal intervention protocol. The protocol comprised two medical-food interventions separated by washout periods: MF1 contained alpha-lactalbumin, inulin, and fructo-oligosaccharides, whereas MF2 contained the MF1 formulation supplemented with sodium butyrate. Clinical assessments, gut microbiota profiling, and fecal and systemic fatty acid measurements were performed at predefined study time points.

resultsSeizure response varied substantially between participants. Two subjects showed a 52% and 57% reduction in monthly seizure frequency during MF1, whereas two different participants experienced reductions greater than 90% during MF2 (94% and 100%, respectively). At the cohort level, the lowest median seizure frequency was observed at the final study time point. A progressive decrease in CDD severity scale scores was also observed over the course of the study. Intervention phases coincided with transient enrichment of short-chain fatty acid (SCFA)-producing genera, including Faecalibacterium, Blautia, and Dorea. Microbiota composition differed between responders and non-responders: higher seizure burden was linked to increased Veillonella, whereas lower seizure frequency corresponded to enrichment of Dialister and Gemmiger. Fecal and systemic SCFA concentrations generally decreased during intervention phases, regardless of clinical response. SIGNIFICANCE: Overall, these findings support a possible interaction between nutritional supplementation, microbial dynamics, and clinical manifestations in CDD. Larger studies will be necessary to clarify the therapeutic relevance of personalized microbiota-targeted approaches in CDD-related epilepsy. PLAIN LANGUAGE SUMMARY: CDKL5 deficiency disorder (CDD) is a rare condition that causes severe developmental difficulties and seizures that are difficult to control. We studied whether two medical food interventions targeting the gut microbiota, one of which also contained sodium butyrate, could influence seizures, disease severity, gut microbiota composition, and metabolite production in people with CDD. Some participants experienced substantial reductions in seizure frequency alongside changes in gut bacteria, although responses varied considerably between individuals. These preliminary findings suggest that microbiota-targeted, non-pharmacological approaches may have potential as supportive strategies in CDD, but larger studies are needed to confirm these observations.

Indexed as

butyratecdkl5epilepsymicrobiota‐gut‐brain axis

Identifiers

PMID42867482
PMCPMC13660742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.